2021
DOI: 10.3389/fphar.2021.661606
|View full text |Cite
|
Sign up to set email alerts
|

Targeting Tumor-Associated Antigen: A Promising CAR-T Therapeutic Strategy for Glioblastoma Treatment

Abstract: Chimeric antigen receptor T cells (CAR-T) therapy is a prospective therapeutic strategy for blood cancers tumor, especially leukemia, but it is not effective for solid tumors. Glioblastoma (GBM) is a highly immunosuppressive and deadly malignant tumor with poor responses to immunotherapies. Although CAR-T therapeutic strategies were used for glioma in preclinical trials, the current proliferation activity of CAR-T is not sufficient, and malignant glioma usually recruit immunosuppressive cells to form a tumor m… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
6
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 10 publications
(8 citation statements)
references
References 105 publications
0
6
0
Order By: Relevance
“…The transmembrane domain is responsible for connecting the extracellular binding domain with the intracellular signal domain and fixing it on the cell membrane. 294 , 295 The intracellular signaling region, including the CD3-zeta domain and the costimulatory domain(s), transduces the signal of antigen recognition to the cell, mediating T-cell activation. The evolution of CAR-T cells has undergone four generations.…”
Section: Cellular Immunotherapymentioning
confidence: 99%
“…The transmembrane domain is responsible for connecting the extracellular binding domain with the intracellular signal domain and fixing it on the cell membrane. 294 , 295 The intracellular signaling region, including the CD3-zeta domain and the costimulatory domain(s), transduces the signal of antigen recognition to the cell, mediating T-cell activation. The evolution of CAR-T cells has undergone four generations.…”
Section: Cellular Immunotherapymentioning
confidence: 99%
“…In GBM, there is a relative lack of TSA [ 51 ]. CAR-T targets mostly TAA, often expressed in small amounts in normal tissues [ 52 ]. Consequently, CAR-T cells invariably harm normal tissues expressing the target antigens while simultaneously eradicating tumor cells.…”
Section: Car-t Cell Therapy In Gbmmentioning
confidence: 99%
“…Immunosuppressive TME [7,8,14,22,36,66,[75][76][77][78][79][80][81][82][83] • CAR-T cells that secrete cytokines or antibodies that lead to antibody-dependent cell-mediated cytotoxicity [16,32,36…”
Section: Current Challenges Potential Solutionsmentioning
confidence: 99%
“…However, PD-L1 is upregulated in TAMs and GBM cells, which leads to immune cell dysfunction through inhibition of T cells after binding PD-1 [ 79 ]. An increased expression of inhibitory ligands is, therefore, associated with worse patient outcomes due to immune escape of the tumor [ 80 , 81 ]. CLTA-4 is another inhibitory immune checkpoint expressed on T cells that binds CD80 and CD86 expressed by APCs.…”
Section: Challengesmentioning
confidence: 99%